for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Applied DNA Sciences Inc

APDN.OQ

Latest Trade

11.00USD

Change

2.09(+23.46%)

Volume

1,441,167

Today's Range

9.17

 - 

12.84

52 Week Range

2.53

 - 

16.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.91
Open
9.91
Volume
1,441,167
3M AVG Volume
20.89
Today's High
12.84
Today's Low
9.17
52 Week High
16.39
52 Week Low
2.53
Shares Out (MIL)
7.47
Market Cap (MIL)
82.18
Forward P/E
-9.65
Dividend (Yield %)
--

Next Event

Applied DNA Sciences Inc Annual Shareholders Meeting

Latest Developments

More

U.S. FDA Says Genetic Variants Of Sars-Cov-2 May Lead To False Negative Results With Molecular Tests For Detection Of Sars-Cov-2

Applied DNA Sciences Sees Q1 Revenue $1.3 Million To $1.6 Million

Applied DNA Reports Q4 Loss Per Share $0.82

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Applied DNA Sciences Inc

Applied DNA Sciences, Inc. is engaged in creating security solutions addressing the challenges of modern commerce. The Company is also engaged in the large-scale production of specific deoxyribonucleic acid (DNA) sequences using the polymerase chain reaction (PCR). Its principal technology platform includes SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon. Its SigNify IF portable DNA reader provides definitive real-time authentication of SigNature DNA in the field-DNA becomes a solution for supply chain integrity. SigNature DNA is the Company's platform ingredient, at the core of all its security solutions. It provides forensic power and protection for a range of applications. SigNature T DNA is a tagging and authentication system specifically designed for textiles and apparel. DNAnet is a DNA marker that can be used to definitively link evidence and offenders to specific crime scenes and help return stolen or lost property to its rightful owner.

Industry

Chemical Manufacturing

Contact Info

50 Health Sciences Dr

STONY BROOK, NY

11790-3349

United States

+1.631.2408800

http://www.adnas.com/

Executive Leadership

James A. Hayward

Chairman of the Board, President, Chief Executive Officer

Beth M Jantzen

Chief Financial Officer

Judith Murrah

Chief Information Officer

Ming-Hwa Liang

Secretary, Strategic Technology Development Officer

Robert B. Catell

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-16.000

2019

-10.460

2020

-3.320

2021(E)

-1.140
Price To Earnings (TTM)
--
Price To Sales (TTM)
42.55
Price To Book (MRQ)
9.89
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
41.03
LT Debt To Equity (MRQ)
9.05
Return on Investment (TTM)
-309.85
Return on Equity (TTM)
-174.82

Latest News

Latest News

Applied DNA to initiate clinical trial of Covid-19 vaccine for cats

Applied DNA Sciences plans to initiate clinical trial of one of its five LineaDNA vaccine candidates for veterinary use to prevent coronavirus infections in domestic cats, the diagnostic test maker said on Wednesday.

BRIEF-Applied Dna Sciences - Forms Clinical Testing Subsidiary To Maximize Utility Of FDA Eua-Approved Linea™ Covid-19 Assay Kit

* APPLIED DNA SCIENCES - FORMS CLINICAL TESTING SUBSIDIARY TO MAXIMIZE UTILITY OF FDA EUA-APPROVED LINEA™ COVID-19 ASSAY KIT

BRIEF-Applied DNA Accepted Into U.S. FDA’S Emerging Technology Program, Creating Pathway For Molecular Tagging Of Pharmaceuticals And Packaging

* APPLIED DNA ACCEPTED INTO U.S. FDA’S EMERGING TECHNOLOGY PROGRAM, CREATING PATHWAY FOR MOLECULAR TAGGING OF PHARMACEUTICALS AND PACKAGING

BRIEF-Applied DNA Ships Covid-19 Lineardna Vaccine Candidates To Italian Development Partner To Begin Preclinical Animal Testing

* APPLIED DNA SHIPS COVID-19 LINEARDNA™ VACCINE CANDIDATES TO ITALIAN DEVELOPMENT PARTNER TO BEGIN PRECLINICAL ANIMAL TESTING

BRIEF-Applied DNA Sciences Signs A 5-Year Pact With Montblanc-Simplo GMBH

* APPLIED DNA SIGNS 5-YEAR AGREEMENT WITH ICONIC WRITING INSTRUMENT SPECIALIST MONTBLANC-SIMPLO GMBH TO PROVIDE SIGNATURE® DNA WITH BEACON® TO PRESTIGE MONTBLANC CLIENTS

BRIEF-Applied DNA Reports Q2 Loss Per Share Of $0.07

* APPLIED DNA REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS

BRIEF-Applied DNA Signs Agreements With Colorcon For Molecular Tagging In Pharmaceutical, Nutraceutical Markets

* APPLIED DNA SIGNS DEFINITIVE AGREEMENTS WITH COLORCON FOR MOLECULAR TAGGING IN THE PHARMACEUTICAL AND NUTRACEUTICAL MARKETS

BRIEF-Applied DNA Reports Q1 Loss Per Share $0.12

* APPLIED DNA REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-DNA Q4 EBITDA EUR 65.7​ mln

* REG-DNA PLC'S FINANCIAL STATEMENTS BULLETIN 2017: DNA'S NET SALES AND OPERATING RESULT REACH RECORD LEVELS IN 2017

BRIEF-Applied DNA Sciences Establishes New Central DNA Testing Laboratory In India

* APPLIED DNA SCIENCES INC SAYS HAS ESTABLISHED A CENTRAL DNA TESTING LABORATORY IN AHMEDABAD, INDIA, PROVIDING FULL FORENSIC AUTHENTICATION SERVICES Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up